TY - JOUR T1 - Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for <sup>18</sup>F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 210 LP - 216 DO - 10.2967/jnumed.118.222513 VL - 61 IS - 2 AU - Bernard H.E. Jansen AU - Robin W. Jansen AU - Maurits Wondergem AU - Sandra Srbljin AU - John M.H. de Klerk AU - Birgit I. Lissenberg-Witte AU - André N. Vis AU - Reindert J.A. van Moorselaar AU - Ronald Boellaard AU - Otto S. Hoekstra AU - Daniela E. Oprea-Lager Y1 - 2020/02/01 UR - http://jnm.snmjournals.org/content/61/2/210.abstract N2 - Biochemically recurrent prostate cancer (BCR) is the main indication to perform prostate-specific membrane antigen PET/CT. However, localizing BCR with prostate-specific membrane antigen PET/CT remains challenging in patients with low prostate-specific antigen (PSA) values. Here, we studied the impact of advanced PET image reconstruction methods on BCR localization and interobserver agreement with 18F-DCFPyL PET/CT scans in patients with BCR and low PSA values. Methods: Twenty-four patients with BCR and a PSA level of less than 2.0 ng/mL were included. PET images were reconstructed with 4-mm voxels and 2-mm voxels, both with and without point-spread function. All scans were interpreted by 4 nuclear medicine physicians. Additionally, PET examinations of 5 patients with primary prostate cancer and confirmed absence of lymph node metastases (after lymph node dissection) were included, to assess the risk of introducing false-positive findings when using advanced reconstruction. Calculation of BCR localization rates (scan positivity) was based on consensus among our readers (≥3 readers regarding a scan positive for BCR), as well as the individual scan interpretations of the readers. Results: In the consensus analysis, BCR localization rates were not higher using advanced reconstruction (62.5%–66.7%) than using 4-mm reconstruction (62.5%). On the basis of individual readings, however, more scans were positive using 2-mm reconstruction (74.0%; 95% confidence interval [CI], 65.0%–82.9%) (P = 0.027) and 2-mm reconstruction with point-spread function (75.0%; 95% CI, 66.2%–83.8%) (P = 0.014) than 4-mm reconstruction (65.6%; 95% CI, 56.0%–75.3%). A higher number of lesions was detected on the 2-mm scans (median, 2 lesions; interquartile range, 1–3) than the 4-mm scans (median, 1; interquartile range, 0–3; P = 0.008). The advanced reconstruction methods did not increase interobserver agreement (80.6%–84.7%), compared with the 4-mm scans (75.7%, P = 0.08–0.25). In the patients with primary prostate cancer, an equal number of false-positive lesions was observed among the different reconstruction methods (overall, n = 13). Conclusion: Applying advanced image reconstruction for 18F-DCFPyL PET/CT scans did not increase BCR localization in patients with BCR and low PSA values (reader consensus). Yet, the increased number of positive individual readings may imply that further development of image reconstruction methods holds potential to improve BCR localization. No improved interobserver agreement was observed with advanced reconstruction compared with standard 4-mm reconstruction. ER -